Cellular pharmacokinetic mechanisms of adriamycin resistance and its modulation by 20(S)-ginsenoside Rh2 in MCF-7/Adr cells

British Journal of Pharmacology

Volumn 165, Issue 1, 2012, Pages 120-134

  Zhang, Jingwei ^a   Zhou, Fang ^a   Wu, Xiaolan ^a   Zhang, Xiaoxuan ^a   Chen, Yuancheng ^a,b   Zha, Beth S ^a   Niu, Fang ^a   Lu, Meng ^a   Hao, Gang ^a   Sun, Yuan ^a   Sun, Jianguo ^a   Peng, Ying ^a   Wang, Guangji ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

20(S) ginsenoside Rh2; adriamycin resistance; cellular pharmacokinetic; mechanisms; P gp inhibition

Indexed keywords

DOXORUBICIN; GINSENOSIDE RH 2; GLYCOPROTEIN P;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL FRACTIONATION; CELL GROWTH; CELL STRAIN MCF 7; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG RESISTANCE; DRUG TRANSPORT; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTIBIOTICS, ANTINEOPLASTIC; CARBOXY-LYASES; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GINSENOSIDES; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; SUBCELLULAR FRACTIONS;

EID: 82955184560     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01505.x     Document Type: Article

References (46)

1. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA, (2005). Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol 34: 405-412. (Pubitemid 40645331)
2. Arcamone F, Animati F, Capranico G, Lombardi P, Pratesi G, Manzini S, et al,. (1997). New developments in antitumor anthracyclines. Pharmacol Ther 76: 117-124. (Pubitemid 28078564)
3. Baldini N, Scotlandi K, Serra M, Shikita T, Zini N, Ognibene A, et al,. (1995). Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution. Eur J Cell Biol 68: 226-239.
4. Barcia-Macay M, Mouaden F, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F, (2008). Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts). J Antimicrob Chemother 61: 1288-1294. (Pubitemid 351760774)
5. Bradford MM, (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
6. Chen Y, Cao Y, Zhou J, Liu X, (2009). Mechanism-based pharmacokinetic-pharmacodynamic modeling of bidirectional effect of danshensu on plasma homocysteine in rats. Pharm Res 26: 1863-1873.
7. Duvvuri M, Krise JP, (2005). Intracellular drug sequestration events associated with the emergence of multidrug resistance: a mechanistic review. Front Biosci 10: 1499-1509. (Pubitemid 40529015)
8. Duvvuri M, Feng W, Mathis A, Krise JP, (2004). A cell fractionation approach for the quantitative analysis of subcellular drug disposition. Pharm Res 21: 26-32. (Pubitemid 38122288)
9. Ferrao P, Sincock P, Cole S, Ashman L, (2001). Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia. Leuk Res 25: 395-405. (Pubitemid 32294284)
10. Gong Y, Duvvuri M, Krise JP, (2003). Separate roles for the Golgi apparatus and lysosomes in the sequestration of drugs in the multidrug-resistant human leukemic cell line HL-60. J Biol Chem 278: 50234-50239. (Pubitemid 37548864)
11. Guha P, Dey A, Sen R, Chatterjee M, Chattopadhyay S, Bandyopadhyay SK, (2011). Intracellular GSH depletion triggered mitochondrial Bax translocation to accomplish resveratrol-induced apoptosis in the U937 cell line. J Pharmacol Exp Ther 336: 206-214.
12. Halder B, Bhattacharya U, Mukhopadhyay S, Giri AK, (2008). Molecular mechanism of black tea polyphenols induced apoptosis in human skin cancer cells: involvement of Bax translocation and mitochondria mediated death cascade. Carcinogenesis 29: 129-138. (Pubitemid 351201751)
13. Hien TT, Kim HG, Han EH, Kang KW, Jeong HG, (2010). Molecular mechanism of suppression of MDR1 by puerarin from Pueraria lobata via NF-kappaB pathway and cAMP-responsive element transcriptional activity-dependent up-regulation of AMP-activated protein kinase in breast cancer MCF-7/adr cells. Mol Nutr Food Res 54: 918-928.
14. Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L, et al,. (2008). Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 68: 5301-5308.
15. Hung DY, Siebert GA, Chang P, Roberts MS, (2005). Hepatic pharmacokinetics of taurocholate in the normal and cholestatic rat liver. Br J Pharmacol 145: 57-65. (Pubitemid 40675549)
16. Ivanina AV, Sokolova IM, (2008). Effects of cadmium exposure on expression and activity of P-glycoprotein in eastern oysters, Crassostrea virginica Gmelin. Aquat Toxicol 88: 19-28.
17. Jia WW, Bu X, Philips D, Yan H, Liu G, Chen X, et al,. (2004). Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy. Can J Physiol Pharmacol 82: 431-437. (Pubitemid 39388382)
18. Jiang YS, Jin ZX, Umehara H, Ota T, (2010). Cholesterol-dependent induction of dendrite formation by ginsenoside Rh2 in cultured melanoma cells. Int J Mol Med 26: 787-793.
19. Jung LL, Zamboni WC, (2001). Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it? Drug Resist Updat 4: 273-288.
20. Kikuchi Y, Sasa H, Kita T, Hirata J, Tode T, Nagata I, (1991). Inhibition of human ovarian cancer cell proliferation in vitro by ginsenoside Rh2 and adjuvant effects to cisplatin in vivo. Anticancer Drugs 2: 63-67.
21. Kitagawa I, Yoshikawa M, Yoshihara M, Hayashi T, Taniyama T, (1983). [Chemical studies of crude drugs (1). Constituents of Ginseng radix rubra]. Yakugaku Zasshi 103: 612-622. (Pubitemid 13027064)
22. Kitazono M, Sumizawa T, Takebayashi Y, Chen ZS, Furukawa T, Nagayama S, et al,. (1999). Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 91: 1647-1653. (Pubitemid 29479932)
23. Korper S, Nolte F, Rojewski MT, Thiel E, Schrezenmeier H, (2003). The K+ channel openers diazoxide and NS1619 induce depolarization of mitochondria and have differential effects on cell Ca2+ in CD34+ cell line KG-1a. Exp Hematol 31: 815-823. (Pubitemid 37075975)
24. Kroger N, Achterrath W, Hegewisch-Becker S, Mross K, Zander AR, (1999). Current options in treatment of anthracycline-resistant breast cancer. Cancer Treat Rev 25: 279-291. (Pubitemid 29507299)
25. Larsen AK, Escargueil AE, Skladanowski A, (2000). Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 85: 217-229. (Pubitemid 30160791)
26. Meijerman I, Beijnen JH, Schellens JH, (2008). Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. Cancer Treat Rev 34: 505-520.
27. Meschini S, Calcabrini A, Monti E, Del Bufalo D, Stringaro A, Dolfini E, et al,. (2000). Intracellular P-glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells. Int J Cancer 87: 615-628. (Pubitemid 30620402)
28. Munteanu E, Verdier M, Grandjean-Forestier F, Stenger C, Jayat-Vignoles C, Huet S, et al,. (2006). Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells. Biochem Pharmacol 71: 1162-1174. (Pubitemid 43357897)
29. Ota K, Ito K, Akahira J, Sato N, Onogawa T, Moriya T, et al,. (2007). Expression of organic cation transporter SLC22A16 in human epithelial ovarian cancer: a possible role of the adriamycin importer. Int J Gynecol Pathol 26: 334-340. (Pubitemid 46986072)
30. Peleg M, (1997). Modeling microbial populations with the original and modified versions of the continuous and discrete logistic equations. Crit Rev Food Sci Nutr 37: 471-490. (Pubitemid 127500971)
31. Rivera E, (2010). Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes. Am J Clin Oncol 33: 176-185.
32. Sato N, Ito K, Onogawa T, Akahira J, Unno M, Abe T, et al,. (2007). Expression of organic cation transporter SLC22A16 in human endometria. Int J Gynecol Pathol 26: 53-60. (Pubitemid 46036959)
33. Serrone L, Hersey P, (1999). The chemoresistance of human malignant melanoma: an update. Melanoma Res 9: 51-58. (Pubitemid 29169989)
34. Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA, et al,. (2008). Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther 324: 95-102. (Pubitemid 350294163)
35. Shen F, Bailey BJ, Chu S, Bence AK, Xue X, Erickson P, et al,. (2009). Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by valspodar (PSC833) in multidrug resistance human cancer cells. J Pharmacol Exp Ther 330: 423-429.
36. Siebert GA, Hung DY, Chang P, Roberts MS, (2004). Ion-trapping, microsomal binding, and unbound drug distribution in the hepatic retention of basic drugs. J Pharmacol Exp Ther 308: 228-235. (Pubitemid 38090722)
37. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al,. (1985). Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85. (Pubitemid 16258399)
38. Solazzo M, Fantappie O, Lasagna N, Sassoli C, Nosi D, Mazzanti R, (2006). P-gp localization in mitochondria and its functional characterization in multiple drug-resistant cell lines. Exp Cell Res 312: 4070-4078. (Pubitemid 44834517)
39. Stavrovskaya AA, (2000). Cellular mechanisms of multidrug resistance of tumor cells. Biochem (Mosc) 65: 95-106.
40. Tao LY, Liang YJ, Wang F, Chen LM, Yan YY, Dai CL, et al,. (2009). Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function. Cancer Chemother Pharmacol 64: 961-969.
41. Xie X, Eberding A, Madera C, Fazli L, Jia W, Goldenberg L, et al,. (2006). Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models. J Urol 175: 1926-1931.
42. Yi JS, Choo HJ, Cho BR, Kim HM, Kim YN, Ham YM, et al,. (2009). Ginsenoside Rh2 induces ligand-independent Fas activation via lipid raft disruption. Biochem Biophys Res Commun 385: 154-159.
43. Yu ST, Chen TM, Tseng SY, Chen YH, (2007). Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Biochem Biophys Res Commun 358: 79-84.
44. Zhang X, Shedden K, Rosania GR, (2006). A cell-based molecular transport simulator for pharmacokinetic prediction and cheminformatic exploration. Mol Pharm 3: 704-716. (Pubitemid 46087486)
45. Zhang J, Zhou F, Wu X, Gu Y, Ai H, Zheng Y, et al,. (2010). 20(S)-ginsenoside rh2 noncompetitively inhibits p-glycoprotein in vitro and in vivo: a case for herb-drug interactions. Drug Metab Dispos 38: 2179-2187.
46. Zhou F, Zhang J, Li P, Niu F, Wu X, Wang G, et al,. (2011). Toward a new age of cellular pharmacokinetics in drug discovery. Drug Metab Rev 43: 335-345.